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Abstract
Background: Cervical cancer, a leading cause of cancer deaths in women in developing countries can be prevented 
primarily by vaccinating adolescent girls and women against infection by the human papillomavirus (HPV) before their 
first sexual exposure, and secondarily through screening and treatment of identified precancerous lesions.
Aim: To determine the awareness and acceptability of the HPV vaccine and screening for cervical cancer among female 
health-care workers in Enugu, southeastern Nigeria. 
Materials and Methods: Questionnaires were administered to a cross-section of 177 female health-care workers 
selected systematically from the University of Nigeria Teaching Hospital (UNTH), Enugu, Nigeria. Statistical analysis 
was both descriptive and inferential at 95% confidence level using the Statistical Package for Social Sciences (SPSS) 
computer software version 16. A P value of less than 0.05 was considered statistically significant.
Results: The awareness of screening for cervical cancer (91%) was significantly higher than that of the HPV vaccine 
(62.7%) [odds ratio (OR): 0.17; 95% confidence interval (CI): 0.09–0.30]. However, the acceptability rate of the HPV 
vaccine (91.0%) was significantly higher than that of cervical screening (71.4%) (OR: 4.04;95% CI: 1.94–8.42)]. Only 
25 (14.1%) of the health-care workers had done cervical screening, but 30 (49.2%) of the 61respondents with adolescent 
daughters had immunized their daughters with the HPV vaccine. Although no reason was given for the low participation 
in cervical screening, cost and availability of HPV vaccine was a major deterrent for the latter. 
Conclusion: With more public enlightenment, available and affordable HPV vaccine appears to hold the key for 
prevention of cervical cancer in developing countries where the burden is high.
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Introduction
Cervical cancer has claimed the lives of many women 
worldwide and it is estimated that about 80% or more of 
the world burden of cervical cancer is in the developing 
countries.[1,2] This preventable cancer has a long precancerous 
stage and during this interval, screening could be done, and 
any precancerous lesions identified could be adequately treated 
to prevent progression to the invasive cancer stage.[3] Human 
papilloma virus (HPV), a sexually transmitted virus has been 
implicated as the causative agent. The new prevention strategy 
for cervical cancer is directed at immunization against this 
HPV infection prior to the first sexual exposure as a form of 
primary prevention or to screen for evidence of preinvasive 
lesions of the cervix as a form of secondary prevention. 
Acceptability of human papilloma virus vaccine and 
cervical cancer screening among female health-care 
workers in Enugu, Southeast Nigeria
EO Ugwu, SN Obi, PC Ezechukwu, II Okafor1, AO Ugwu2
Department of Obstetrics and Gynaecology and 2Haematology and Immunology, University of Nigeria 
Teaching Hospital, 1Obstetrics and Gynaecology, Enugu State University of Science and Technology 
Teaching Hospital Parklane, Enugu, Nigeria





250 Nigerian Journal of Clinical Practice • Apr-Jun 2013 • Vol 16 • Issue 2
Ugwu, et al.: Acceptability of HPV vaccine by female health workers
The Papanicoloau (Pap) smear has been the screening tool 
commonly used and it has reduced the incidence of cervical 
cancer in the developed countries by over 70%.[2,4] However, 
in the developing world, where the resources are very limited 
and screening centers are either not available or are sparsely 
distributed, the screening programs have been unsuccessful 
and ineffective in reducing the disease burden.[5] This is 
further compounded by the fact that both the women and 
health-care providers in these poor-resource countries often 
lack information about cervical cancer as a disease entity, its 
causative agent, and how cost effective it is to prevent it.[2]
In the recent past, the discovery of the HPV vaccine has 
transformed the prospects for reducing the incidence of 
cervical cancer on a global scale.[6] As HPV is sexually 
transmitted and most women become infected within three 
years of commencement of sexual activity, the vaccine if 
given before the first sexual exposure, will help develop 
immunity against the virus prior to the exposure. The 
vaccines have been found to have remarkable efficacy, 
achieving more than 98% protection in randomized clinical 
trials against cervical intraepithelial neoplasia (CIN) grades 
2 and 3 and adenocarcinoma in situ.[7] The effectiveness 
of a vaccine delivery program depends largely upon the 
awareness of the health-care providers about the vaccine 
and their attitude in terms of acceptability of the vaccine.[8] 
These factors influence the willingness or readiness of the 
health-care providers to recommend the vaccine to others.[8] 
This study is therefore meant to assess the awareness and 
acceptability of the cervical cancer vaccine and that of the 
Pap smear among female health-care workers.
Materials and Methods
Study area
Enugu State is one of the five states in the Southeast 
geopolitical zone of Nigeria, and its capital city is Enugu. 
It lies within the West African rainforest region (latitude: 
5°55’ and 7°10' N and longitude: 6°50’ and 7°55’ E), through 
a land area of approximately 8,000 km2.[9] According to 
the 2006 population census, the Enugu State and Enugu 
metropolis have a population of 3,257,298 and 722,664, 
respectively with a female to male ratio of approximately 
1:1.[10] The state has an annual growth rate of population 
of about 2.28% and the population is predominantly Igbos 
with pockets of other tribes.[9]
The UNTH, Enugu is the pioneer teaching hospital in 
southeastern Nigeria. It is owned by the federal government 
of Nigeria and is currently located at Ituku-Ozalla, at the 
outskirts of Enugu.
Study design and sample selection
This is a questionnaire-based cross-sectional survey of female 
health-care workers at the UNTH, Enugu, southeastern 
Nigeria. The study took place between 3 July and 6 November, 
2009. The nonprofessional female health-care workers such 
as the hospital attendants, orderlies, cleaners, and so on were 
excluded from the study. The administrative health- care 
workers were also excluded. Using an acceptability rate of 
88% for the HPV vaccine obtained in a previous study from 
Gaborone, Botswana,[11] at a confidence level of 95% and 
error margin of 5%, the calculated minimum sample size was 
162. However, a sample size of 200 was used for the study. The 
hospital had a record of 801 professional female health- care 
workers comprising 204 female doctors, 369 nurses, 88 
laboratory scientists, 64 pharmacists, 40 dieticians, and 36 
physiotherapists. A sampling frame of each group of the 
above-mentioned health-care workers was first obtained and 
a multistage sampling technique was employed to select the 
sample of 200 respondents from the various groups. In the 
first stage, a stratified sampling method was used to assign 
the sample size of 200 to the six groups of female health- care 
workers as follows: 51 to the group of doctors, 92 to the 
group of nurses, 22 to the group of laboratory scientists, 16 
to the group of pharmacists, 10 to the group of dieticians, 
and 9 to the category of physiotherapists, proportionately. 
In the second stage, the systematic sampling technique was 
employed to select the required sample size of 200 from the 
various groups of health-care workers, first by using a simple 
random sampling method to select one name from the first four 
names in a prepared sampling frame of each group of workers, 
and thereafter, selecting every fourth name in the prepared 
sampling frame of each group of workers starting from the first 
name already selected by the simple random sampling method.
Following individual counseling of eligible participants, 
self- administered, structured and pretested questionnaires 
were distributed to the consenting selected women by 
trained medical interns. Ethical clearance for the study 
was obtained from the Institutional Review Board of the 
UNTH, Enugu.
Data sought included sociodemographic characteristics 
of respondents, awareness and acceptability of the HPV 
vaccine and the Pap smear, as well as uptake of the HPV 
vaccine by the adolescent daughters of the respondents and 
uptake of the Pap smear by the respondents themselves. The 
questionnaire was pretested among 15 health-care workers 
at the Enugu State University Teaching Hospital, Parklane, 
Enugu.
Data analysis was both descriptive and inferential at the 
95% confidence level using the SPSS software version 16. 0 
[SPSS Inc., Chicago, Ill.]. Proportions were compared with 
the Pearson chi-squared test. A P-value of less than 0.05 
was considered statistically significant.
Acceptability of HPV vaccine was defined as the willingness 
of the health-care worker to recommend the vaccine to 
her adolescent daughters, other adolescents, and other 
sexually unexposed young women, whereas acceptability of 
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screening for cervical cancer was defined as the willingness 
of the health-care worker to do the Pap smear herself and to 
recommend it to other women singly or during health-care 
talk among female folk.
Results
Of the 200 questionnaires distributed, 177 were retrieved, 
giving a response rate of 88.5%. The mean age of respondents 
was 30.6 ± 2.7 years (range: 20-65). One hundred and seventy 
(96%) were of the Ibo tribe. The seven others were made up 
of 3 (1.7%) Yoruba, 2 (1.1%) Idomas, 1 (0.6%) Igala, and 
1 (0.6%) Urhobo. One hundred and six (59.9%) respondents 
were married, whereas 81 (40.1%) were single. Forty-five 
(25.4%) were doctors, 81 (45.8%) were nurses, 19 (10.7%) 
were laboratory scientists, 14 (7.9%) were pharmacists, 
9 (5.1%) were dieticians, and 9 (5.1%) were physiotherapists.
One hundred and fifty-two (85.9%) were aware of cervical 
cancer and that it was preventable, whereas 25 (14.1%) were 
not aware that the cancer was preventable. One hundred and 
forty-nine (84.2%) knew that HPV was the causative agent 
implicated in cancer of the cervix and one hundred and 
thirty-eight (78.0%) knew that HPV was sexually transmitted.
One hundred and eleven (62.7%) respondents were aware 
of the HPV vaccine and 101 (91%) of them were willing to 
recommend it to their adolescent daughters, other adolescents, 
or sexually unexposed young women. Of the 111 respondents 
aware of the HPV vaccine, 96 were married, of whom 61 
had adolescent daughters. Thirty (49.2%) of the 61married 
respondents with adolescent daughters had immunized their 
daughters with the vaccine. The married respondents who had 
not immunized their adolescent daughters cited cost (92%) 
and unavailability (76%) of the vaccine as major reasons. 
Among the respondents aware of the vaccine, 93 (83.8%) 
thought that the use of the vaccine would reduce the 
incidence of cancer of the cervix, whereas 18 (16.2%) did not 
know whether it would reduce it or not. Ninety-two (82.9%) 
respondents wanted the vaccine to be included in the national 
immunization schedule. One hundred and sixty-one (91%) 
respondents were aware of the Pap smear, and 148 (83.6%) of 
its ability to detect precancerous lesions. The awareness of the 
Pap smear (91%) was significantly higher than that of the HPV 
vaccine (62.7%) (OR: 0.17; 95% CI: 0.09–0.30) [Table1]. 
One hundred and fifteen (71.4%) of those aware of the Pap 
smear were willing to use it themselves and to recommend it 
to fellow women. The acceptability rate of the HPV vaccine 
(91.0%) was however significantly higher than that of the 
Pap smear (71.4%) (OR: 4.04; 95% CI: 1.94–8.42) [Table1]. 
Twenty-five (15.5%) of the women aware of the Pap smear had 
done the screening in the past. The rest (84.5%) had never 
done it and gave no reason for not doing the test. However, 
they were hopeful that they would do the test in the future.
Discussion
This study demonstrated a significantly higher level of 
acceptability of the HPV vaccine as a method of preventing 
cervical cancer despite the significantly lower level of 
awareness of the vaccine compared to that of the Pap smear. 
This implies that our health-care workers were much more 
willing to vaccinate their adolescent daughters or recommend 
the vaccine to adolescent daughters of other women than 
doing the Pap smear test themselves or recommending it 
to other women. As the effectiveness of a vaccine delivery 
program depends largely on the acceptability of the vaccine 
among the health-care workers as noted by previous authors,[8] 
it may imply therefore that this new method of prevention of 
cervical cancer may be more effective than the traditional 
Pap smear approach at least in this study population. 
The significantly lower awareness of the HPV vaccine 
compared to that of the Pap smear suggests the need for 
public enlightenment. Even though the health-care workers 
expressed high awareness of cervical cancer as a disease entity 
and HPV as the causative agent, it may not be appropriate 
to attribute the high acceptability rate of the HPV vaccine 
obtained in this study to the mere awareness of the disease 
condition, as previous studies among university students in 
Nigeria and women seeking health-care services in Ghana 
and Kenya with limited awareness of cervical cancer and HPV 
vaccine prior to health education still demonstrated high 
acceptability of the vaccine.[12-14] What is more important is 
that the HPV vaccine is acceptable to the health-care workers 
whose attitude and dispositions contribute to determining the 
success of any new health-care program. Nevertheless, further 
study may help unravel the predictors of acceptability of HPV 
vaccine among our health-care workers.
The uptake of HPV vaccine among the adolescent daughters 
of respondents in this study was fairly high. It is known that 
public enlightenment campaigns often have the potential of 
creating awareness and improving acceptability and uptake 
of most health-care programs and health-care workers no 
doubt are key partners in achieving this success. The impact 
of public enlightenment on the acceptability of HPV vaccine 
was evident in a recent study from Northwest Tanzania.[15] 
However, the availability of the vaccine at an affordable rate 
is also a key factor in this realization, based on the evidence in 
this study. Moreover, certain sociocultural issues such as fear 
of quality of the vaccine, adverse effects, effects on fertility, 
and promotion of promiscuity as identified in a previous 
study from developing countries may need to be addressed.[16] 
Despite the high level of awareness and acceptability of the 
Pap smear in the study, the uptake by the respondents was 
very low. A previous study from the study center in 2010 and 
from South Africa in 2002 reported similar findings among 
women of high social and educational background.[17,18] This 
may be due to poor health-seeking behavior and attitude to 
seeking routine preventive medical procedures among people 
in developing countries, and the psychological unpleasantness 
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associated with gynecological examinations.[19] Nevertheless, 
their readiness to recommend both the preventive procedures 
and the fact that most of them wanted the vaccine included 
in the national immunization schedule further emphasized 
their awareness of the inherent risk of not participating in the 
preventive programme.
The limitations of this study included the fact that the 
perception of the mothers about the HPV vaccine in terms 
of acceptability as assessed in this study may differ from those 
of their 10 to 14-year-old adolescents. However, decisions 
about uptake of the vaccine may not even be made by these 
adolescents; so, acceptability of vaccines among their mothers 
may be a better reflection of the societal response to the 
introduction of the new vaccine. Second, the main outcome 
variable in this study was the intention to recommend the 
HPV vaccine rather than the actual recommendation of the 
vaccine. However, intention has been associated with actual 
behaviors including provider immunization behaviors, in a 
previous study.[20]
Conclusion/Recommendation
The acceptability of the HPV vaccine as a method of 
preventing cervical cancer is higher than that of the Pap smear 
despite the significantly lower level of awareness of the vaccine 
compared to the Pap smear. Available and affordable HPV 
vaccine appears to hold the key for the prevention of cervical 
cancer in developing countries where the burden is high. 
Public enlightenment campaigns, in addition to subsidizing 
the cost of the vaccine and making it easily available are 
recommended strategies that could improve its use.
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Table 1:Awareness and acceptability of HPV vaccine and cervical screening
Yes (%) No (%) Total P value OR (95% CI)
Awareness
HPV vaccine 111 (62.7) 66 (37.3) 177 <0.0001 0.17 (0.09-0.30)
Cervical cancer screening 161 (91) 16 (9) 177
Acceptability
HPV vaccine 101 (91) 10 (9) 111 <0.0001 4.04 (1.94-8.42)
Cervical cancer screening 115 (71.4)  
46 (28.6)
161
OR=Odds ratio, CI=Confidence interval, HPV=Human papilloma virus
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